Patient-reported outcome measurements in clinical trials in Saudi Arabia: A cross-sectional analysis of ClinicalTrials.gov

沙特阿拉伯临床试验中患者报告结局指标的测量:ClinicalTrials.gov 的横断面分析

阅读:2

Abstract

OBJECTIVES: To quantify use of patient-reported outcomes (PROs) in interventional trials conducted in Saudi Arabia and to determine whether PRO usage varies according to key trial characteristics. METHODS: The ClinicalTrials.gov database was searched to identify all interventional trials located in Saudi Arabia. Two authors screened each trial's primary and secondary outcomes and categorized each trial into: (1) trials in which PROs were mentioned or (2) trials in which PROs were not mentioned. The Chi-square test was used to examine associations between PRO use and certain trial characteristics. RESULTS: The search identified 933 trials. Forty percent (n=371) reported PROs as primary (n=141, 38%) or secondary (n=178, 48%) outcomes or both (n=52, 14%). The number of PRO instruments was 535. Pain was the most common PRO (n=164, 31%). Trials characteristics associated with more use of PROs included nonindustry-sponsored trials, trials focusing on nondrug interventions, phase 3 trials and trials conducted exclusively in Saudi Arabia. CONCLUSION: Forty percent of the registered clinical trials in Saudi Arabia used at least one PRO. This highlights the need to address barriers to PRO use to facilitate generation of local evidence.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。